Media Coverage

UCLA Health Continues to Transform Cancer Care

As we celebrate the 100-year milestone of UCLA, we'd like to acknowledge the contributions of UCLA Health’s Jonsson Comprehensive Cancer Center. Since its inception, the center has dedicated itself to providing the best in leading-edge and traditional cancer treatments and expertly guiding the next generation of medical research. Transformative research work from the IUO co-Director Arie Belldegrun and IUO Board Member Dennis Slamon was highlighted. UCLA Magazine >

Transforming Cancer Care
  • Arie Belldegrun, MD developed the first FDA approved CAR-T cell therapy.
  • Dennis Slamon, MD, PhD (pictured right) led to the development of a breast cancer drug that has saved thousands of women’s lives.

July 26, 2022 - UCLA researchers awarded Department of Defense funding to improve prostate cancer treatment outcomes. A team led by Paul C Boutros, PhD, MBA, professor in the departments of human genetics and urology and interim vice dean for research at the David Geffen School of Medicine at UCLA and director of the UCLA Jonsson Comprehensive Cancer Center’s Cancer Data Science program has been awarded over $2.7 million in research funding from the U.S. Department of Defense to support two projects that will use computational models and DNA sequencing to improve prostate cancer treatment outcomes. The project is co-led by Huihui Ye, MD, MS, chief of Genitourinary Pathology at UCLA. The 3-year grants go into effect July 2022. UCLA Health Newsroom >


February 16, 2022 - Dr. Amar Kishan, MD, lead author – An analysis by Amar Kishan, MD, indicates that MRI-guided radiotherapy appears to lead to fewer side effects from treatment for prostate cancer. UCLA Health News >


January 20, 2022 - Dr. Amar Kishan, MD, lead author – “Jonsson Comprehensive Cancer Center meta-analysis may help guide treatment planning for patients with high-risk prostate cancer.  “An international effort consisting of a consortium of 16 research centers in collaboration with two international cooperative trial groups found that patients receiving high-dose external beam radiation therapy alone may benefit from androgen deprivation therapy (ADT) lasting longer than 18 months, while those with external beam radiation therapy and a brachytherapy boost – the implantation of radioactive seeds to deliver a higher dose to the prostate – may be optimally managed with 18 months of ADT or possible less.  Results are published in the Jan. 20 issue of JAMA Oncology.” UCLA Health News >


January 17, 2022 – Dr. Amar Kishan, MD, lead author – “A new meta-analysis of randomized, controlled clinical trials provides strong support for adding androgen deprivation therapy (ADT) to definitive radiotherapy (RT) for the treatment of prostate cancer, projecting that doing so would prevent one cancer from metastasizing for every 10 to 15 men treated.  The analysis, published in Lancet Oncology, was conducted through the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium, a group formed in 2020 to serve as a data repository from international trial groups.  The MARCAP consortium was co-founded by Dr. Amar Kishan….”  UCLA Health News >


January 14, 2022 – Dr. Christopher Saigal - Prostate cancer ADT has fewer cardiovascular risks than expected per Renal & Urology News – “Christopher Saigal, MD, MPH, professor and vice chair of urology at the David Geffen School of Medicine at the University of California in Los Angeles, said “this study will need to be validated because it is uncertain how accurately this one individual health system captured all of the MACE events in this patient population.”


January 13, 2022 – Dr. Amar Kishan – Genetics predicts the toxic side effects to prostate cancer radiotherapy – “For the first time, researchers….used prostate cancer patients’ DNA to create a model that appears to predict who will have side effects from radiation.  ‘One of the biggest goals of our research program is to try to minimize toxicity and improve quality of life after treatment,’” said Dr. Kishan, lead author and vice chair of clinical and lational research in the Department of Radiation Oncology at UCLA. Published in Radiotherapy and Oncology. UCLA Health News >


January 7, 2022 – Dr. Amar Kishan – UCLA Health researcher receives $1.1 million grant to help improve radiation treatment of prostate cancer – The grant from the Department of Defense spearheads a project exploring basic science concepts in the treatment of prostate cancer with the project anticipated to have a major impact by improving radiotherapy delivery technology and enhancing understanding of underlying biology of radioresistance.  With the new grant, Dr. Kishan – under the mentorship of fellow IUO Member Dr. Paul Boutros, director of Cancer Data Science at UCLA – “…will evaluate two separate-but-linked hypotheses.  The first is that by allowing real-time adjustments of radiotherapy dose delivery based on changes in the shape and position of the urethra and trigone, clinicians can significantly decrease the proportion of patients in whom these structures are overdosed during radiotherapy.  The second hypothesis is that by evaluating the genome of the patients with viable or visible tumor two years after radiotherapy, the group will identify a significant increase in markers of aggressiveness.”  UCLA Health News >  Grant information: W81XWH-22-1-0044 / Optimizing Radiation Delivery and Dissecting the Response to Radiation for Patients with Localized Prostate Cancer.


December 29, 2021 - Drs. Karim Chamie, Isla Garraway, Amar U. Kishan, Nick Nickols, Matthew Rettig, Christopher Saigal, Michael Steinberg – “UCLA-led meta analysis of seven randomized trials found an “unexpected result”: Although Black men appeared to have more aggressive disease when they enrolled in clinical trials of radiation therapy for prostate cancer, their treatment outcomes and disease-specific outcomes were better than those of their white counterparts.  “These results provide high-level evidence challenging the common belief that Black men who are diagnosed with prostate cancer will necessarily have a worse prognosis than white men,” said Dr. Amar Kishan, a co-senior author of the article in the December 29th issue of JAMA Network Open.  UCLA Health News > Read more >  


December 14, 2021 - Drs. Johannes Czernin, Jeremie Calais, Amar U. Kishan, Nicholas Nikols, Robert Reiter, Matthew Rettig, Michael Xiang – “UCLA-Led Study Provides First Indirect Evidence That PSMA PET/CT Surpasses Conventional Imaging in Detecting Occult Prostate Cancer Spread and Predicting Long-Term Course and Outcomes.”  Read more here > and here >


December 10, 2021 - Dr. Isla Garraway - Summarizes SUO session on early detection and treatment of prostate cancer for an interview with Urology Times. "It’s really important to look at the pathology we’ve learned before considering these patients for active surveillance treatment,” says Isla Garraway, MD, PhD, associate professor of urology at the David Geffen School of Medicine at UCLA, member of the UCLA Institute of Urological Oncology, Jonsson Comprehensive Cancer Center, and Broad Center for Regenerative Medicine and Stem Cell Research at UCLA.  Read more > 


December 3, 2021 - Dr. Mark Litwin – Testicular Cancer with Dr. Mark Litwin. On NBCLX "If you find something you think is suspicious --a lumpy bumpy area inside the testicle--get yourself to a good doctor... a urologist typically and then he or she can make a diagnosis."--Mark S. Litwin, MD, chair of the department of urology at UCLA Health; director, Testicular Cancer Program, Institute of Urologic Oncology; and member of the UCLA Jonsson Comprehensive Cancer Center's Cancer Control and Survivorship Program.  Read more >